Presidential Orders Direct Rescheduling of Cannabis to Schedule III

The order calls for more research into how marijuana and CBD affect specific populations, including a focus on long-term health effects in adolescents and young adults. For people with mental health conditions, the impact is mixed — some may benefit from new treatment options for conditions like anxiety or PTSD, but research could also reveal risks. The emphasis on closing the knowledge gap between current use and medical understanding is important for this group.

This executive order directly benefits the millions of Americans who use marijuana for medical purposes. By directing the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III, it acknowledges marijuana's accepted medical uses and could lead to better doctor guidance, safer products, and reduced legal stigma. The roughly 6 million registered medical marijuana patients across 40+ states stand to gain from improved research on dosing, drug interactions, and long-term effects.

Nearly 1 in 4 U.S. adults live with chronic pain, and 6 in 10 medical marijuana users report using it for pain management. This order pushes for real-world research on how marijuana and CBD actually help people with chronic conditions like pain, nausea from chemotherapy, and anorexia related to medical conditions. Better research means doctors can give clearer advice on whether these treatments are safe and effective for specific conditions, potentially reducing reliance on opioids.

The executive order specifically cites veterans as a group that benefits from medical marijuana, noting that 20% of veterans in one survey reported using fewer opioids after starting medical marijuana. Veterans dealing with chronic pain, PTSD, and other service-related conditions could benefit from expanded research and clearer medical guidance. Rescheduling could also reduce barriers that prevent VA doctors from discussing marijuana as a treatment option.

The order specifically tasks the Administrator of the Centers for Medicare and Medicaid Services with developing research methods for hemp-derived cannabinoid products. If marijuana moves to Schedule III, it could eventually open the door for Medicare to cover FDA-approved marijuana-based treatments. Seniors are highlighted throughout the order — 1 in 10 used marijuana in the past year, and many take multiple medications, making research on drug interactions especially important for this population.

CMS is directly tasked in this order with developing research models for cannabinoid products. If marijuana is rescheduled to Schedule III and FDA-approved treatments emerge, Medicaid programs could potentially cover these treatments for low-income patients. This could be particularly meaningful for Medicaid enrollees who use marijuana for chronic pain but currently pay out of pocket.

Hemp and CBD product manufacturers stand to benefit from clearer federal regulatory frameworks. The order directs the White House to work with Congress on updating rules for hemp-derived CBD products, including THC limits per serving and labeling standards. Small businesses in the hemp and CBD industry have struggled with confusing and shifting federal rules, and a more stable regulatory environment could help them plan, invest, and compete fairly.

Hemp farmers could benefit from clearer federal rules around hemp-derived cannabinoid products. The order addresses the legal complexity surrounding full-spectrum CBD products and THC thresholds, which directly affects what hemp farmers can grow and sell. By working toward a regulatory framework that balances consumer safety with market access, the order could stabilize demand for hemp crops.